Tandem Diabetes Care (NASDAQ:TNDM) saw its stock decline by 5% Wednesday morning after Citi downgraded the company from Neutral to Sell, citing increasing challenges from competitors. Analyst Joanne ...

Sanofi India denies reports of Lantus sale, calls media reports ‘unfounded’ The French pharmaceutical major has reportedly slashed the asking price for Lantus from an initial Rs 3,000 crore to ...

Biosimilar insulin glargine access in Europe correlates with significant price reductions of originator products, enhancing affordability and accessibility. The study observed a 21.6% average ...

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for low-income health clinics.

Houston-based rBIO has invented a new process to churn out insulin at higher yields using custom-made bacteria.

$35 price cap Sanofi established a $35 monthly cap on out-of-pocket costs for Lantus, its most widely prescribed insulin in the US, for all patients with commercial insurance starting January 1.

Sanofi is joining the nation’s two other major insulin manufacturers in offering either price caps or savings programs that lower the cost of the drugs to $35 for many patients.

GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin ...

All Americans with a valid prescription, regardless of their insurance status, can use GoodRx at more than 70,000 retail pharmacies to access a 30-day supply of Lantus for $35.

GoodRx, Sanofi partner on $35 insulin It’s unclear how much the partnership will improve access to affordable insulin given other recent initiatives from drugmakers and public insurance programs.

Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...

This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap out-of-pocket costs at $35 for all patients with commercial insurance, which goes into effect ...